Glaxo announces drug research projects in Siena

(AGI) Siena, Feb 20 - Multinational drug giant GlaxoSmithKline(GSK) is to fund research into innovative drug development atthe University of Siena in Italy. Dr Duncan Holmes, EuropeanHead of the Discovery Partnerships with Academia researchprogramme, will present 11 research projects at the universityon Wednesday. These will include anti-cancer drugs and drugsfor combating serious diseases, such as multiple sclerosis andRett syndrome. Research will also be undertaken intoantibiotic-resistant bacteria. The university said theprogramme was a first step in a long-term collaboration betweenthe university and GSK, which would involve research proposalsusing shared skills,

(AGI) Siena, Feb 20 - Multinational drug giant GlaxoSmithKline(GSK) is to fund research into innovative drug development atthe University of Siena in Italy. Dr Duncan Holmes, EuropeanHead of the Discovery Partnerships with Academia researchprogramme, will present 11 research projects at the universityon Wednesday. These will include anti-cancer drugs and drugsfor combating serious diseases, such as multiple sclerosis andRett syndrome. Research will also be undertaken intoantibiotic-resistant bacteria. The university said theprogramme was a first step in a long-term collaboration betweenthe university and GSK, which would involve research proposalsusing shared skills, facilities and resources to developinnovative drugs. By the end of March, GSK will take overNovartis facilities in Siena and Rosiai, employing more than2,000 people, to produce vaccines, excluding flu vaccines.These will remain the preserve of Novartis. Siena UniversityRector Angelo Riccboni, Glaxo Technology Transfer Manager forCentral Northern Italy Doris Fendt, and the DiscoveryPartnerships with Academia programme head of externalrelations, Stephane Huet, will also be at the presentation.(AGI) . .